Skip to content
Home » Medical image data platform Callisto conducts medical image generation AI joint research with Hiroshima University Hospital

Medical image data platform Callisto conducts medical image generation AI joint research with Hiroshima University Hospital

Medical image data platform Callisto conducts medical image
generation AI joint research with Hiroshima University Hospital
*View in browser* *Calisto Co., Ltd.*
Press release: April 4, 2024
**
Medical image data platform Callisto conducts medical image generation AI joint research with Hiroshima University Hospital
* Callisto, a medical image data platform that can be used immediately for medical AI/drug discovery AI research and development
Callisto Co., Ltd. (Headquarters: Toshima-ku, Tokyo; Representative Director and CEO: Chang-hee Han; hereinafter referred to as
“Callisto”), a startup from the University of Tokyo that works on “DataHub”, is working with Hiroshima University Hospital on medical image generation AI using CT/MRI data. We would like to inform you that we are conducting joint research on *

* [Background of joint research] *
In recent years, OpenAI’s “Sora” and Stability AI’s “Stable Diffusion” Video generation AI based on Transformer technology such as “3” is causing a paradigm shift in various fields including art, education, and advertising. Similarly, as long as there is high-quality and diverse medical image data, generative AI can be used in the radiotherapy field as well, in the form of “generating prognostic images,” “generating medical images that are difficult to obtain,” and “generating images using other modalities.” This technology should be able to greatly contribute to the realization of
“personalized medicine.” Therefore, the Hiroshima University Hospital Radiology Department, which is known for its utilization and research of medical AI, and Callisto, whose representative is Callis, Japan’s best young medical AI researcher, have come together to discuss the necessity of such medical image generation AI. Therefore, we have decided to carry out this joint research.
* [Summary of joint research] *
Based on the provision of CT/MRI data and clinical information by Hiroshima University Hospital Radiology Department, creation of datasets, and advice, proposals, and evaluations from a clinical perspective, Callisto will “generate prognostic images” and “improve medical information that is difficult to obtain.” We will design and experiment with algorithms based on transformer technology for “image generation” and “different modality image generation.” Using high-quality and diverse medical image data accumulated at hospitals, Callisto will continue to conduct research in collaboration with the Department of Radiology, Hiroshima University Hospital, with the aim of producing impactful research results that will change clinical practice.

* [Comment from the principal investigator at Hiroshima University Hospital] * Hiroshima University Hospital Radiology Department Dr. Daisuke Kawahara Our research group is “Medical Innovation by Medical”.
With the theme of “Physics”, we aim to revolutionize medical care through medical AI research and development. By utilizing Hiroshima University Hospital’s medical image data and clinical information and proceeding with joint research with Callisto, which has know-how in AI research and development, we will be able to create innovative medical care that can not only be used in actual medical settings but also attract attention from around the world. Create AI. Together with Callisto, we will promote advanced generative AI research and development in the medical AI field.

* ■Company profile*
*Company name* Callisto Inc.
* Business details * 1. Operation of a medical image data platform for medical AI/drug discovery AI research and development
2. Contract development and consulting of drug discovery AI/medical AI * Officers * Representative Director Han Chang-hee (Charis)
Outside Director Kato Motomimi
*Location* 5F Diamond Gate Ikebukuro, 1-16-15 Minamiikebukuro, Toshima-ku, Tokyo 171-0022
*Established* June 27, 2022
*Company URL* https://callisto-ai.com

If you have any questions or concerns regarding data provision, data set purchase, drug discovery AI/medical AI R&D outsourcing/consulting, interviews/writing/lectures, collaboration, investment, recruitment, or any other matters, please contact us here.

*Email address for inquiries*: inquiry@callisto-ai.com
*About details about this release*
https://prtimes.jp/main/html/rd/p/000000006.000116169.html

*Download press release materials*
https://prtimes.jp/im/action.php?run=html&page=releaseimage&company_id=116169&release_id=6


Unsubscribe HTML email

%d